MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 4:144-146, (2004)
© American Society for Pharmacology and Experimental Therapeutics
10.112/4.3.3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lynch, O. T.
Right arrow Articles by Gadina, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lynch, O. T.
Right arrow Articles by Gadina, M.

Viewpoint

Ubiquitination for Activation: New Directions in the NF-{kappa}B Roadmap

Oonagh T. Lynch and Massimo Gadina

Department of Micrbiology and Immunology, Queen’s University, Belfast BT9 7BL, Northern Ireland UK

SUMMARY

Signal transduction through the T cell receptor (TCR) and a costimulatory molecule, CD28, results in the stimulation of multiple signaling pathways, leading to the activation of several transcription factors including activator protein–1 (AP-1), nuclear factor of activated T cells (NF-AT), and nuclear factor kappa B (NF-{kappa}B). The molecular mechanisms by which NF-{kappa}B is activated by TCR–CD28 have only recently become known. New findings indicate that the adaptor molecules CARMA1 and Bcl10 are essential to the process. Additionally, a critical role for MALT1/paracaspase has been identified. MALT1, CARMA1, and Bcl10 form a tripartite protein complex, in which Bcl10 is thought to facilitate the oligomerization of MALT1 monomers. Overexpression of MALT1, as observed in a subset of lymphoma patients, leads to the potent activation of NF-{kappa}B, suggesting that MALT1 might stimulate (directly or indirectly) the kinase complex [IKK, inhibitor of NF-{kappa}B (I{kappa}B) kinase] responsible for activating cytoplasmic NF-{kappa}B for translocation into the nucleus. Moreover, the MALT1–CARMA1–Bcl10 complex is responsible for ubiquitination of NEMO, a step that appears to be critical for TCR-induced NF-{kappa}B activation but not for induction mediated by other stimuli such as TNF or IL-1.




This article has been cited by other articles:


Home page
Genes Dev.Home page
M. S. Hayden and S. Ghosh
Signaling to NF-{kappa}B
Genes & Dev., September 15, 2004; 18(18): 2195 - 2224.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.